Reardon, D., Akabani, G., Friedman, A., Friedman, H., Herndon, J., McLendon, R., … Bigner, D. (2004). Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. In NEURO-ONCOLOGY (Vol. 6, pp. 381–381). Toronto, CANADA: DUKE UNIV PRESS.

Reardon, D., G. Akabani, A. Friedman, H. Friedman, J. Herndon, R. McLendon, J. Quinn, et al. “Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.” In NEURO-ONCOLOGY, 6:381–381. DUKE UNIV PRESS, 2004.

Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, et al. Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 381–381.

Reardon, D., et al. “Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors.” NEURO-ONCOLOGY, vol. 6, no. 4, DUKE UNIV PRESS, 2004, pp. 381–381.

Reardon D, Akabani G, Friedman A, Friedman H, Herndon J, McLendon R, Quinn J, Rich J, Vredenburgh J, Penne K, Sampson J, Gururangan S, Shafman T, Wong T, Dowell J, Dunn R, Badruddoja M, Desjardins A, Affronti M, Allen D, Jackson S, Zeigler K, Silverman S, Tourt-Uhlig S, Coleman R, Zalutsky N, Bigner D. Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 381–381.